Andorra vs Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD): Immunization, Hib3
Immunization, Hib3 over time
- Andorra
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
How they compare
Andorra currently reports 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), a difference of 14.3%.
That makes Andorra's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s.
Across all 27 years both countries report, Andorra has been ahead every year.
Andorra ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st of 191 countries.
Andorra has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Andorra | Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 67.5% | 0.0% | 67.5% | Andorra |
| 2000s | 94.0% | 11.7% | 82.3% | Andorra |
| 2010s | 97.9% | 67.9% | 30.0% | Andorra |
| 2020s | 97.6% | 82.5% | 15.1% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Andorra or Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Andorra, at 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) as of 2024.
- What is the difference in immunization, hib3 between Andorra and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- 14.3%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- 27 years are reported by both, from 1998 to 2024.
- How do Andorra and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) rank globally for immunization, hib3?
- Andorra ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.